Brexucabtagene autoleucel - Biologic Drug Details

Summary for brexucabtagene autoleucel

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1
Recent Clinical Trials:	See clinical trials for brexucabtagene autoleucel

Recent Clinical Trials for brexucabtagene autoleucel

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Bankhead-Coley Florida Biomedical Research Program	PHASE2
H. Lee Moffitt Cancer Center and Research Institute	PHASE2
Eli Lilly and Company	PHASE2

See all brexucabtagene autoleucel clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for brexucabtagene autoleucel Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for brexucabtagene autoleucel Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Kite Pharma Inc.	TECARTUS	brexucabtagene autoleucel	For Injection	125703		2037-09-08	DrugPatentWatch analysis and company disclosures
Kite Pharma Inc.	TECARTUS	brexucabtagene autoleucel	For Injection	125703		2038-06-29	DrugPatentWatch analysis and company disclosures
Kite Pharma Inc.	TECARTUS	brexucabtagene autoleucel	For Injection	125703			DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for brexucabtagene autoleucel Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source

International Patents for brexucabtagene autoleucel

Country	Patent Number	Estimated Expiration
Spain	2984684
Argentina	115634
China	109072243

Market Dynamics and Financial Trajectory for Brexucabtagene Autoleucel

Last updated: February 23, 2026

What Is Brexucabtagene Autoleucel?

Brexucabtagene autoleucel (brand name Tecartus) is a CD19-directed CAR T-cell therapy approved by the FDA in July 2020 for relapsed or refractory mantle cell lymphoma (R/R MCL) in adult patients. It is developed by Kite Pharma, a Gilead Sciences subsidiary. The therapy involves extracting a patient’s T cells, genetically modifying them to target CD19 antigens, then reinfusing them to fight cancer.

What Are the Market Drivers?

1. Focus on Relapsed/Refractory Mantle Cell Lymphoma

Brexcucabtagene autoleucel targets a niche within hematologic malignancies, specifically R/R MCL, an aggressive B-cell lymphoma. The unmet need in this indication is significant; standard treatments such as chemotherapy and BTK inhibitors have limited efficacy in refractory cases.

2. Increasing Adoption of CAR T-Cell Therapies

The global CAR T-cell therapy market is expanding rapidly. Key drivers include:

• Growing pipeline of approved and pipeline therapies.
• Enhancements in manufacturing and safety profiles.
• Increased physician familiarity and infrastructure for cell therapy.

3. Market Expansion into Other Indications

Research aims to extend brexucabtagene autoleucel to other indications such as:

• Marginal zone lymphoma.
• Other B-cell malignancies.
• Potential application in autoimmune diseases.

4. Competitive Landscape

Brexucabtagene autoleucel faces competition from other CD19-targeted therapies such as:

• Kymriah (Novartis).
• Lisocabtagene maraleucel (Juno/BMS).
• Idecabtagene vicleucel (BMS).

However, the approval for R/R MCL positions it favorably within its niche.

Market Size and Revenue Potential

Hematologic Malignancies

The global hematologic cancer market was valued at approximately USD 23 billion in 2022, with CAR T-cell therapies representing a growing segment.

Mantle Cell Lymphoma Market

• Estimated incidence: 5000 new cases annually in the U.S.
• R/R MCL constitutes roughly 20-30% of MCL cases.
• The market potential in the U.S. is projected between USD 400-600 million annually.

Revenue Estimates

Kite Pharma’s reported sales of Tecartus in 2022 were approximately USD 100 million, driven by:

• U.S. sales.
• Initial European launches.

Market analysts predict sales could reach USD 500 million annually within five years, contingent on expanded indications, reimbursement strategies, and sales infrastructure.

Reimbursement and Pricing

Tecartus is priced at approximately USD 373,000 per treatment in the U.S. (as per the Centers for Medicare & Medicaid Services — CMS). In Europe, pricing varies but generally ranges from EUR 250,000 to EUR 350,000 per case.

Reimbursement policies influence market penetration. The U.S. CMS has implemented novel payment models, such as the “Coverage with Evidence Development” approach, to facilitate access.

Manufacturing and Supply Chain Considerations

Manufacturing complexity remains a barrier to expansion. The process involves expensive, time-intensive cell extraction, genetic modification, and expansion. Post-approval scaling has led to increased manufacturing capacity, but logistical delays impact access.

Production Capacity

• Kite Pharma has increased production facilities, with multiple centers in the U.S. and Europe.
• Estimated capacity: 1,000–1,500 therapies annually.

Supply Challenges

• Logistics of cell transportation.
• Variability in manufacturing timelines.
• Need for expedited processing in urgent cases.

Future Growth Cycles

Pipeline and Indications

Data from ongoing trials suggests potential expansion into:

• Other B-cell neoplasms, including diffuse large B-cell lymphoma (DLBCL).
• Novel CAR T constructs with improved safety and efficacy.

Regulatory Milestones

Upcoming approvals could include:

• Additional indications for Tecartus.
• Combination therapy approvals.
• New manufacturing process approvals for increased scalability.

Market Challenges

• Emergence of allogeneic (“off-the-shelf”) CAR T therapies.
• Competition from bispecific antibodies.
• Reimbursement hurdles in non-U.S. markets.

Financial Trajectory Forecast

Year	Estimated Sales (USD billion)	Key Drivers
2022	0.1	U.S. initial launch
2023	0.2–0.3	Expanded indications, increased capacity
2025	0.5–0.7	Broader clinical acceptance, reimbursement
2030	USD 1+	Market expansion, pipeline success

Key Takeaways

Brexucabtagene autoleucel’s market trajectory depends on clinical expansion, manufacturing scalability, and reimbursement policies. It holds potential for substantial revenue growth within B-cell malignancies, particularly mantle cell lymphoma, supported by increasing adoption of CAR T therapies. Competition and logistical issues pose ongoing risks, but pipeline progress and regulatory milestones can influence future market share.

FAQs

1. What is the main clinical indication for brexucabtagene autoleucel?
   It is approved for relapsed or refractory mantle cell lymphoma in adults.

2. How does the pricing compare to other CAR T therapies?
   The treatment costs around USD 373,000 per infusion in the U.S., similar to other CAR T therapies like Kymriah.

3. What are the primary barriers to market expansion?
   Manufacturing complexity, logistical challenges, and reimbursement hurdles.

4. Are there plans to expand indications for Tecartus?
   Ongoing trials aim to extend its use to other B-cell cancers such as DLBCL.

5. What is the projected revenue for Tecartus in the next five years?
   Estimated to reach USD 500 million annually in five years, under favorable market conditions.

---

References

[1] Gilead Sciences. (2020). FDA Approves Tecartus™ for Mantle Cell Lymphoma. FDA.
[2] MarketWatch. (2022). CAR T cell therapy market size.
[3] Centers for Medicare & Medicaid Services. (2022). Reimbursement policies for CAR T therapies.
[4] IQVIA. (2022). Hematology market report.
[5] Grand View Research. (2023). CAR T-cell therapy market forecast.